The collaboration includes $56 million in upfront payments to AbCellera and up to $792 million in potential option fees and milestone payments for any program Jazz exercises its option to develop

Jazz has the exclusive option to develop and commercialize therapeutic antibodies resulting from the collaboration

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) and AbCellera (NASDAQ:ABCL) today announced a preclinical research collaboration, option and license agreement to discover and develop next-generation T-cell engaging (TCE) multispecific antibodies. The collaboration will leverage AbCellera's antibody discovery engine to deliver optimized development candidates for multiple gastrointestinal (GI) cancers and other solid tumors.